Table 2.
GATA3 single nucleotide polymorphisms and breast cancer outcomes in S8897 trial
| Genotype | Treated Group (n=441) |
Untreated Group (n=799) |
||||
|---|---|---|---|---|---|---|
| # events/patients | Adjusted HR (95% CI) | Adjusted P | # events/patients | Adjusted HR (95% CI) | Adjusted P | |
| A. Overall survival | ||||||
| rs3802604 | ||||||
| AA | 31/164 | 1.00 | 96/337 | 1.00 | ||
| GA | 51/206 | 1.36 (0.87-2.14) | 0.18 | 99/342 | 1.07 (0.81-1.42) | 0.64 |
| GG | 30/70 | 2.45 (1.48-4.05) | 0.0005 | 27/166 | 0.78 (0.51-1.20) | 0.27 |
| Per risk allele | 1.57 (1.21-2.03) | 0.0007 | 0.94 (0.78-1.13) | 0.48 | ||
| rs568727 | ||||||
| CC | 28/160 | 1.00 | 95/328 | 1.00 | ||
| AC | 52/204 | 1.50 (0.94-2.39) | 0.09 | 102/357 | 1.03 (0.78-1.36) | 0.86 |
| AA | 32/77 | 2.57 (1.43-4.30) | 0.0003 | 24/111 | 0.74 (0.47-1.16) | 0.19 |
| Per risk allele | 1.59 (1.23-2.06) | 0.0005 | 0.91 (0.75-1.10) | 0.32 | ||
| B. Disease-free survival | ||||||
| rs3802604 | ||||||
| AA | 49/164 | 1.00 | 134/337 | 1.00 | ||
| GA | 66/206 | 1.08 (0.74-1.56) | 0.69 | 145/342 | 1.15 (0.91-1.45) | 0.25 |
| GG | 37/70 | 1.95 (1.27-2.99) | 0.002 | 38/116 | 0.80 (0.56-1.15) | 0.24 |
| Per risk allele | 1.38 (1.10-1.73) | 0.005 | 0.96 (0.82-1.12) | 0.62 | ||
| rs568727 | ||||||
| CC | 45/160 | 1.00 | 131/328 | 1.00 | ||
| AC | 68/204 | 1.22 (0.83-1.79) | 0.31 | 153/357 | 1.14 (0.90-1.44) | 0.28 |
| AA | 39/77 | 2.02 (1.31-3.12) | 0.001 | 32/111 | 0.71 (0.48-1.04) | 0.08 |
| Per risk allele | 1.41 (1.13-1.76) | 0.003 | 0.92 (0.79-1.08) | 0.33 | ||
Footnote: Hazard ratios (HRs), 95% confidence intervals (CIs) and p-values were derived from Cox hazard regression models with adjustment for age at enrollment, race and ethnicity, and treatment arms. Estimates of per risk allele were derived from an additive genetic model by treating genotypes as 0, 1 and 2 according to the copy number of risk allele. P-values ≤ 0.001 were considered statistically significant to account for multiple testing for 12 genetic variants in GATA3.